Time filter

Source Type

Bonn, Germany

Agency: Cordis | Branch: FP7 | Program: CSA-CA | Phase: HEALTH-2009-4.1-2 | Award Amount: 848.43K | Year: 2010

The European Consortium for Communicating Stem Cell Research, EUROSTEMCELL, brings together the major current FP6 and FP7 stem cell projects, the European Clinical Research Infrastructure Network, and four internationally recognized European stem cell centres to develop a comprehensive, coordinated platform for collation, dissemination and archiving of information on stem cell biology and regenerative medicine. Our aims are to address the urgent need for trusted, high quality information on stem cells by citizens and stakeholders across Europe, and further to establish a model for large-scale dissemination of Framework-funded research outputs to European publics. Dissemination of key advances will be achieved through a structured approach aimed at reaching European citizens and stakeholders at all educational levels. We will focus on three major dissemination routes: the worldwide web; resources for direct public engagement; and resources for educators. Emphasis will be placed on clear exposition of the potential applications and benefits for citizens of existing knowledge and new developments in stem cell research. To ensure continuous development of best practice, we will iteratively evaluate and refine all activities throughout the project. The project centrepiece will be a multi-lingual website, the European Stem Cell Information Portal www.eurostemcell.org, which we will create and develop as the premier European reference site for stem cell information and discourse. The consortium comprises the principal stem cell laboratories across Europe, including new member states, and additionally offers outstanding expertise in ethical and societal concerns and in evaluating clinical outcomes. This coalition provides unparalleled expertise across the field of stem cell biology and regenerative medicine, and is uniquely placed to achieve the vision of a trusted and accessible European stem cell information resource that promotes and facilitates public dialogue.

Life and Brain GmbH | Date: 2012-06-15

The present invention relates to glioblastoma inhibiting compounds, in particular gambogic acid amid and derivatives thereof for the treatment of glioblastoma. Moreover, methods for determining whether a treatment with the compounds of the invention is suitable for a patient are disclosed.

Life and Brain GmbH | Date: 2013-08-06

The present invention relates to novel therapeutic uses of niclosamide for the treatment of cancer. In particular, a combination of niclosamide or one of its derivatives with an alkylating agent is provided for the treatment of solid tumors. Moreover, niclosamide or one of its derivatives can be used for the treatment of solid tumors characterized by underexpression of NFKBIA. Finally, the invention relates to diagnostic methods for determining whether treatment with niclosamide alone or in combination with an alkylating agent is suitable for a cancer patient.

Life and Brain GmbH | Date: 2013-07-08

The invention relates to a fusion protein and a method for the generation of the fusion protein of the invention. Further, the invention relates to the use of the fusion protein of the invention for the generation of induced pluripotent cells. Moreover, the invention relates to a composition comprising at least one fusion protein of the invention.

Agency: Cordis | Branch: H2020 | Program: RIA | Phase: PHC-03-2015 | Award Amount: 6.00M | Year: 2016

COSYN integrates outstanding European academic and three large Pharma to exploit genomic findings for intellectual disability (ID), autism, and schizophrenia. We capitalise on comorbidity, from clinic to cells and synapses, and have access to large existing samples. We focus on rare genetic variants of strong effect in patients with clinical comorbidity. Our aims are: (1) Understand comorbidity by comparing symptom and syndrome overlap with novel neurobiological criteria; (2) Elucidate mechanisms of comorbidity using neurobiology for the major genomic clue of synaptic dysfunction to unravel the cellular mechanisms of comorbidity; (3) Generate novel neuronal cell models by using advanced technologies to make neurons from carefully selected patients, and use genome editing to create or correct genetic variants. Multiple advanced neuroscience platforms are in place to evaluate an extensive set of molecular and cellular parameters, and to identify alterations in synaptic biology characteristic of ID, autism, and schizophrenia. These cellular models will, with Pharma partners, be up-scaled to provide industry-standard cellular assays for compound screening; (4) Refine diagnostic tools, use novel genomic and cellular features to improve disease classification and discriminate specific patient subtypes; and (5) Case studies in precision medicine: with Pharma partners, identify patients with a genetic change whose consequences can be reproducibly ameliorated in vitro by an approved medication. Recommend to the patient and clinician a double-blinded, N-of-one crossover case study to evaluate the clinical utility of a medication precisely indicated for that person. COSYN is an integrated, state-of-art, bench-to-bedside programme focused on personalised therapeutics. COSYN is a crucial next step in decoding the genetic findings via intensive focus on the clinical and molecular comorbidities of ID, autism, and schizophrenia.

Discover hidden collaborations